Shares of Cohance Lifesciences surged 5.5% to Rs 935 in intraday trade after Jefferies initiated coverage with a ‘Buy’ rating and a target price of Rs 1,150. The global brokerage expressed a bullish outlook on select Indian pharma and CRDMO companies, assigning ‘Buy’ ratings to Cohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences, with an … Read more
Mutual fund investment has become an appealing opportunity for wealth accumulation. A key advantage of this investment avenue is its accessibility, as individuals can start investing with amounts as low as Rs 100 or Rs 200 through Systematic Investment Plans (SIPs). The power of compound interest, given time to grow, has the potential to turn … Read more
Retailer and hypermarket operator Trent and state-owned Bharat Electronics are likely to replace LTI Mindtree and Divi’s Laboratories in the forthcoming rejig in the Nifty index, according to an estimate by Nuvama Alternative & Quantitative Research. The possible changes would lead to an inflow of $429 million or Rs 3,500 crore into Trent and $ … Read more
Divi’s Laboratories Ltd, part of the pharma industry, gave a breakout from an inverse Head & Shoulder pattern on daily charts to hit a fresh 52-week high last week which suggests that the trend is in favour of bulls. Short-term traders can look to buy the stock for a possible target above 4000-4300 levels in … Read more
Brokerage firm BofA Securities has a buy rating on Muthoot Finance and Zomato, and a neutral rating on Bandhan Bank and Divi’s Laboratories. Morgan Stanley maintained an overweight rating on Delhivery. We have collated a list of recommendations from top brokerage firms from ETNow and other sources: BofA Securities on Muthoot Finance: Buy| Target Rs … Read more